ITeos Therapeutics Receivables 2019-2025 | ITOS

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ITeos Therapeutics receivables from 2019 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

ITeos Therapeutics receivables from 2019 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$226.4B
Amgen (AMGN)	$166.3B
Gilead Sciences (GILD)	$141.3B
Vertex Pharmaceuticals (VRTX)	$122.5B
Bristol Myers Squibb (BMY)	$99.7B
CSL (CSLLY)	$85.2B
GSK (GSK)	$77.9B
Regeneron Pharmaceuticals (REGN)	$61.8B
Alnylam Pharmaceuticals (ALNY)	$42.5B
Argenex SE (ARGX)	$35.2B
BioNTech SE (BNTX)	$27.5B
Royalty Pharma (RPRX)	$20.2B
Insmed (INSM)	$19.6B
Biogen (BIIB)	$19.2B
Illumina (ILMN)	$16.6B
Genmab (GNMSF)	$14.9B
Genmab (GMAB)	$14.7B
Incyte (INCY)	$13.7B
Moderna (MRNA)	$13.4B
Exelixis (EXEL)	$12.4B
BioMarin Pharmaceutical (BMRN)	$11.4B
QIAGEN (QGEN)	$11.2B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.4B
Exact Sciences (EXAS)	$9.1B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Bio-Techne Corp (TECH)	$8.7B
Blueprint Medicines (BPMC)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.7B